Sir H N Reliance Foundation Hospital in Mumbai has introduced Maharashtra's first MR Fusion Prostate Biopsy Equipment, marking a significant advancement in cancer care. This state-of-the-art technology combines MRI and ultrasound for precise prostate cancer detection and treatment planning. Compared to conventional methods which typically offer 30% to 40% accuracy, the MR Fusion biopsy equipment boasts an impressive 90% accuracy, crucial for early-stage cancer detection.
Prostate cancer is a significant health concern in India, constituting 3 to 7 percent of all cancers with an annual diagnosis estimate of 33,000 to 42,000 cases. The MR Fusion Biopsy enhances diagnostic accuracy by integrating AI technology to identify abnormal areas marked during the MRI phase, ensuring better cancer detection rates.
One of the key advantages of this technology is its non-invasive approach, performed through the perineum rather than the rectal route. This method reduces the risk of infection and eliminates concerns about rectal bleeding, offering a safer alternative. Dr. Santoshi Janardan Nagaonkar, director of urology, urological oncology & robotic surgery at Sir H N Reliance Foundation Hospital, highlighted that this approach covers the entire prostate gland more comprehensively than traditional methods, facilitating timely and accurate treatment decisions such as radical prostatectomy.
With projections indicating a doubling of prostate cancer cases in India by 2040, the need for advanced diagnostic and treatment technologies is critical. Sir H N Reliance Foundation Hospital, known for its high standards in medical care and infrastructure, including a comprehensive Medical Mall and rigorous JCI accreditation, underscores its commitment to providing world-class healthcare solutions.
This initiative not only enhances patient outcomes but also sets a benchmark in cancer care within Maharashtra, aligning with global standards in medical innovation and patient-centric healthcare delivery.